arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Transcode Therapeutics, Inc.

RNAZ

$4.00 ▼ -0.45 (-10.11%) at close

7 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Transcode Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $2.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -272.5% ↘

FCF / Share $-28.31

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-34.66M

↓ -106.9% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -272.5% is weak on an absolute basis (target > 10%)
Interest CoverageInterest Coverage of -4303.96x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.56x is weak on an absolute basis (target > 1x)

Health Breakdown

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	96.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	98.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	90.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-67.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-58.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-106.9% Weak ↓ Weak Declining Year-over-year change in net income	9.7% Fair ↑ Fair Improving Year-over-year change in net income	-5.6% Weak ↑ Weak Improving Year-over-year change in net income	-156.7% Weak Weak Year-over-year change in net income	-192.0% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.56x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.21x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-272.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	775.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-934.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-454.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	16.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-17.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-214.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-375.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-245.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-68.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	—	—	-33.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-324%)	68.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+358%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-4303.96x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-941.77x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-347.39x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-582.56x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-64.70x Weak Weak Operating income divided by interest expense Optimal: > 5x	-1.84x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-17.81M	$-5.81M	$-2.77M	$-4.97M	$-20.83M	$-828.02K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-52.59	$-1.34K	$-95.77K	$-1.01M	$-605.04K	$-380.95K	—
Free Cash Flow per Share (USD)	$-28.31	—	—	—	—	—	—
Book Value per Share (USD)	$11.27	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$-141.45	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	689,713	12,558	194	17	11	6	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$18.49M	$4.32M	$964.85K	$3.03M	$20.20M	$426.35K	—
Total Equity (USD)	$10.34M	$-2.02M	$1.64M	$3.24M	$20.40M	$-3.41M	$-1.11M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$76.45K	$90.89K	$123.48K	$98.61K	$42.47K	$0.00	—
Net Income, GAAP (USD)	$-34.66M	$-16.75M	$-18.55M	$-17.56M	$-6.84M	$-2.34M	—
Operating Cash Flow (USD)	$-19.52M	$-13.34M	$-18.07M	$-15.76M	$-5.27M	$-492.97K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Transcode Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare RNAZ with peers